AlphaCentric Advisors LLC Purchases 2,500 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

AlphaCentric Advisors LLC increased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 29.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,000 shares of the specialty pharmaceutical company's stock after purchasing an additional 2,500 shares during the quarter. AlphaCentric Advisors LLC's holdings in Jazz Pharmaceuticals were worth $1,174,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Capital World Investors bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth approximately $171,943,000. Swedbank AB bought a new position in shares of Jazz Pharmaceuticals during the second quarter valued at $106,936,000. Vestal Point Capital LP acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $89,175,000. Armistice Capital LLC grew its holdings in shares of Jazz Pharmaceuticals by 108.4% in the 4th quarter. Armistice Capital LLC now owns 651,626 shares of the specialty pharmaceutical company's stock worth $80,150,000 after purchasing an additional 338,882 shares during the last quarter. Finally, Perpetual Ltd increased its position in shares of Jazz Pharmaceuticals by 54.0% during the 1st quarter. Perpetual Ltd now owns 475,018 shares of the specialty pharmaceutical company's stock worth $57,202,000 after purchasing an additional 166,543 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Analysts Set New Price Targets

A number of research firms have commented on JAZZ. Wells Fargo & Company reduced their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 1st. Piper Sandler reduced their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an "overweight" rating on the stock in a report on Thursday, August 1st. The Goldman Sachs Group started coverage on Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They set a "buy" rating and a $169.00 price target on the stock. Barclays cut their price objective on Jazz Pharmaceuticals from $230.00 to $200.00 and set an "overweight" rating for the company in a research report on Friday, May 3rd. Finally, JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a report on Monday, August 19th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $173.07.

Jazz Pharmaceuticals Trading Up 0.4 %

Jazz Pharmaceuticals stock traded up $0.42 during trading hours on Monday, reaching $114.29. 321,578 shares of the company's stock traded hands, compared to its average volume of 667,764. The firm has a market capitalization of $7.21 billion, a price-to-earnings ratio of 23.56, a PEG ratio of 1.76 and a beta of 0.58. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.90 and a current ratio of 2.37. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $146.70. The firm's 50 day moving average is $109.10 and its 200-day moving average is $112.93.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.